- Molecular NameAzithromycin
- SynonymAritromicina [Spanish]; Azithramycine; Azithromycin Dihydrate; Azithromycine [French]; Azithromycinum [Latin]
- Weight748.996
- Drugbank_IDDB00207
- ACS_NO83905-01-5
- Show 3D model
- LogP (experiment)4.02
- LogP (predicted, AB/LogP v2.0)3.36
- pka8.1 and 8.8
- LogD (pH=7, predicted)-0.48
- Solubility (experiment)slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)0.13
- LogSw (predicted, AB/LogsW2.0)2.06
- Sw (mg/ml) (predicted, ACD/Labs)13.72
- No.of HBond Donors5
- No.of HBond Acceptors14
- No.of Rotatable Bonds7
- TPSA180.08
- StatusFDA approved
- AdministrationOral (capsule or suspension), intravenous, ophthalmic
- PharmacologyAn azalide, a subclass of macrolide antibiotics.
- Absorption_value37.0
- Absorption (description)Azithromycin is rapidly absorbed after oral administration with a bioavailability of about 40%.
- Caco_2N/A
- Bioavailability34.0
- Protein binding28.5
- Volume of distribution (VD)31 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmSome demethylation of the drug occurs in the liver
- Half life14 to >40 h
- ExcretionIt is excreted in bile as the unchanged drug and its metabolites (approx. 10 with no microbial activity); more than 50% of a dose is excreted in faeces as the unchanged drug. About 12% of an oral dose is excreted in urine over the course of about a week.
- Urinary Excretion12
- Clerance9 ml/min/kg
- ToxicityPotentially serious side effects of angioedema and cholestatic jaundice were reported
- LD50 (rat)N/A
- LD50 (mouse)N/A